question_number,audience,confidence,consistency,question,answer
1,GP,⬤⬤⬤,███,"What is a QALY and why does it matter for health policy?",
2,GP,⬘⬘⬘,███,"Why can't we just use regular QALYs if people live longer?",
3,GP,⬘⬘⬘,██░,"What does ""unbounded lifespan"" actually mean—will people live forever?",
4,GP,⬘⬘◯,██░,"Is this paper saying death will become optional?",
5,GP,⬘⬘⬘,███,"What's wrong with how we currently evaluate health treatments?",
6,GP,⬘⬘⬘,███,"Why does the paper talk about ""maintenance"" and ""repair""—are we treating people like machines?",
7,GP,⬘⬘⬘,███,"What is the difference between lifespan and healthspan?",
8,GP,⬘⬘◯,█░░,"If I could live indefinitely, would I want to? Is this paper assuming I would?",
9,GP,⬘⬘⬘,███,"What does ""catastrophic failure"" mean in this context?",
10,GP,⬘⬘◯,██░,"Why is this a problem that needs solving now?",
11,MD,⬘◯◯,█░░,"What scientific advances would need to happen for this framework to become relevant?",
12,PM,⬘⬘◯,██░,"How does this framework apply to current health policy, or is it purely futuristic?",
13,MD,⬘◯◯,█░░,"What is the timeline for when unbounded lifespans might become a reality?",
14,MD,⬘⬘⬘,███,"Does this framework assume all diseases will be curable?",
15,MD,⬘⬘⬘,███,"How does the paper define ""repairable"" vs. ""irreversible"" conditions?",
16,MD,⬘⬘⬘,██░,"What counts as a ""catastrophic failure"" vs. a ""repairable degradation""?",
17,MD,⬘⬘◯,██░,"Are there any current conditions that would be classified as ""irreversible harm states""?",
18,MD,⬘⬘◯,██░,"Does the model account for aging as a disease vs. aging as a natural process?",
19,GP,⬘◯◯,█░░,"How does this relate to cryonics or other life extension technologies?",
20,PH,⬘⬘⬘,███,"Does the paper assume people will want to live indefinitely?",
21,PM,⬘⬘⬘,███,"Why is it important that policy evaluation be ""finite""?",
22,HE,⬘⬘⬘,███,"What does ""stable marginal comparisons"" mean in practice?",
23,HE,⬘⬘⬘,███,"Could you give an example of a policy evaluation that would fail the well-posedness axiom?",
24,HE,⬘⬘⬘,███,"How does this axiom differ from standard assumptions in cost-effectiveness analysis?",
25,MA,⬘⬘⬘,███,"Is well-posedness a mathematical requirement or a practical one?",
26,PM,⬘⬘⬘,███,"Why should a health policy not depend on a ""terminal time""?",
27,PM,⬘⬘◯,██░,"Doesn't all budgeting have to assume some time horizon?",
28,HE,⬘⬘⬘,███,"How do current health policies violate horizon invariance?",
29,PM,⬘⬘⬘,███,"If we don't have a fixed endpoint, how do we ever make decisions?",
30,PM,⬘⬘◯,██░,"Is horizon invariance compatible with democratic political cycles?",
31,GP,⬘⬘⬘,███,"What does it mean that health value ""accrues"" rather than exists at a point in time?",
32,MD,⬘⬘⬘,██░,"Why focus on experienced quality rather than objective health status?",
33,HE,⬘⬘⬘,███,"How do we measure ""instantaneous quality of life""?",
34,PH,⬘⬘◯,██░,"Doesn't this ignore the fact that some experiences have lasting effects?",
35,PH,⬘⬘◯,██░,"What about anticipation and memory—don't they affect welfare too?",
36,PH,⬘⬘◯,██░,"Is this axiom committed to hedonism about well-being?",
37,HE,⬘⬘⬘,███,"How does this relate to the EQ-5D and other quality measurement tools?",
38,PH,⬘⬘⬘,██░,"Why shouldn't death have its own ""disvalue"" separate from ending future welfare?",
39,PH,⬘⬘◯,██░,"Doesn't this ignore the badness of death itself (not just loss of future goods)?",
40,PH,⬘⬘◯,██░,"How does this axiom relate to the ""deprivation account"" of death's badness?",
41,PH,⬘⬘⬘,███,"Is this saying death is only bad because you miss out on future experiences?",
42,PH,⬘⬘⬘,███,"What if someone has a very low quality of life—does their death still ""truncate"" welfare?",
43,MD,⬘⬘◯,██░,"Does this framework respect autonomy around end-of-life decisions?",
44,MD,⬘◯◯,█░░,"How would this apply to physician-assisted dying?",
45,PH,⬘⬘⬘,███,"Why is it important to make ethical assumptions ""explicit""?",
46,HE,⬘⬘⬘,███,"What does it mean that time preference is ""hidden inside technical devices""?",
47,HE,⬘⬘⬘,███,"Isn't the choice of discount rate already debated explicitly?",
48,HE,⬘⬘◯,██░,"How do current NICE guidelines violate this axiom?",
49,PH,⬘⬘◯,██░,"What other normative commitments are typically hidden in health economics?",
50,PM,⬘◯◯,█░░,"Does making assumptions explicit actually change policy outcomes?",
51,PM,⬘⬘⬘,███,"What does ""welfare per unit of population time"" mean concretely?",
52,HE,⬘⬘⬘,███,"How is this different from maximizing total QALYs?",
53,PM,⬘⬘⬘,███,"Why should governments think in terms of person-time rather than individuals?",
54,PH,⬘⬘⬘,██░,"Doesn't this ignore the separateness of persons?",
55,PH,⬘⬘⬘,██░,"Is this axiom utilitarian?",
56,MD,⬘⬘◯,██░,"How does this axiom relate to public health surveillance data?",
57,PH,⬘⬘⬘,███,"What does it mean to treat one person's quality-time as ""substitutable"" for another's?",
58,PH,⬘⬘◯,█░░,"Is it ethical to trade off one person's health for another's?",
59,PH,⬘⬘⬘,███,"How does the paper justify interpersonal welfare comparisons?",
60,PH,⬘⬘⬘,██░,"Does the paper claim QALYs are really comparable across people?",
61,MA,⬘⬘⬘,███,"What is ""trajectory convergence over long horizons"" and why does it help?",
62,PH,⬘⬘◯,██░,"Doesn't everyone's experience remain unique even if lifespans are long?",
63,PH,⬘◯◯,█░░,"How does this relate to the capabilities approach to welfare?",
64,PH,⬘⬘⬘,███,"Is this framework compatible with prioritarianism?",
65,PH,⬘⬘◯,██░,"Can the framework accommodate special obligations (to family, etc.)?",
66,GP,⬘⬘⬘,███,"What is a ""controlled continuous-time Markov chain""?",
67,MA,⬘⬘⬘,███,"Why use continuous time rather than discrete time steps?",
68,MD,⬘⬘◯,██░,"What are the states in a realistic health state space?",
69,HE,⬘◯◯,█░░,"How many states would a realistic model need?",
70,MA,⬘⬘⬘,███,"Can the state space be infinite?",
71,MA,⬘⬘⬘,██░,"What is a ""rate kernel"" and how is it estimated?",
72,MA,⬘⬘◯,██░,"How do transition rates vary with age in this model?",
73,MA,⬘⬘⬘,███,"Does the model allow for time-varying transition rates?",
74,MA,⬘⬘⬘,███,"What is ""non-explosiveness"" and why does it matter?",
75,MA,⬘⬘⬘,███,"What are Foster-Lyapunov criteria and when do they apply?",
76,MD,⬘⬘⬘,███,"Can the model handle correlated health states (comorbidities)?",
77,HE,⬘⬘◯,██░,"How does one estimate transition probabilities from epidemiological data?",
78,HE,⬘⬘⬘,███,"What counts as an ""action"" in this framework?",
79,PM,⬘⬘⬘,██░,"Can actions include social determinants of health (housing, income)?",
80,MA,⬘⬘⬘,███,"What is a ""stationary Markov policy""?",
81,HE,⬘⬘⬘,███,"Why restrict to stationary policies—aren't some policies naturally time-varying?",
82,HE,⬘◯◯,█░░,"How does the model handle multi-agent decisions (patient + doctor + insurer)?",
83,MD,⬘⬘⬘,███,"Can the framework model preventive vs. curative interventions differently?",
84,MA,⬘⬘⬘,██░,"What if the action space is continuous (e.g., drug dosage)?",
85,GP,⬘⬘⬘,███,"Why does the model assume ""immediate replacement"" after death?",
86,PH,⬘⬘⬘,███,"Is this saying one person's death doesn't matter because someone else comes along?",
87,MA,⬘⬘⬘,███,"How realistic is the i.i.d. assumption for new entrants?",
88,HE,⬘⬘◯,██░,"What if the initial health distribution changes over time (demographic shifts)?",
89,HE,⬘⬘◯,██░,"How does this relate to overlapping generations models in economics?",
90,PM,⬘⬘◯,██░,"What if birth rates decline—does the framework still apply?",
91,PM,⬘⬘◯,██░,"How does immigration affect the regeneration assumption?",
92,MA,⬘⬘⬘,███,"Is this assumption necessary or just convenient?",
93,MA,⬘⬘◯,██░,"What happens if we relax the independence assumption?",
94,HE,⬘⬘⬘,███,"What exactly is ""QALY flow""—is it a rate or a ratio?",
95,PM,⬘⬘⬘,███,"How do you interpret J(π) = 0.7 in practical terms?",
96,MA,⬘⬘⬘,███,"Why is J(π) always between 0 and 1?",
97,PM,⬘⬘⬘,███,"What does K(π) (cost flow) represent in budget terms?",
98,HE,⬘⬘◯,██░,"How do you convert QALY flow to a monetary value?",
99,PM,⬘◯◯,█░░,"Is there a ""threshold"" for acceptable QALY flow like the £30,000/QALY threshold?",
100,HE,⬘⬘⬘,███,"How does QALY flow compare to quality-adjusted life expectancy?",
101,MA,⬘⬘⬘,███,"What is renewal-reward theory and where does it come from?",
102,GP,⬘⬘⬘,███,"Can you explain the theorem in plain language?",
103,MA,⬘⬘⬘,███,"What conditions are needed for the theorem to hold?",
104,MA,⬘⬘⬘,███,"What happens if the expected cycle length is infinite?",
105,MA,⬘⬘⬘,███,"Does the theorem require ergodicity?",
106,MA,⬘⬘◯,██░,"How quickly does Q(T)/T converge to J(π)?",
107,HE,⬘⬘◯,██░,"What is the rate of convergence and does it matter for policy?",
108,MA,⬘⬘⬘,███,"Can you prove the theorem?",
109,HE,⬘⬘⬘,███,"Why do we need the truncated flow definition?",
110,MA,⬘⬘⬘,███,"What does J⁺(π) ≠ J⁻(π) mean intuitively?",
111,MA,⬘⬘⬘,███,"Under what conditions do the limsup and liminf agree?",
112,MA,⬘⬘◯,██░,"Is there a policy where J⁺ ≠ J⁻? Can you give an example?",
113,HE,⬘⬘⬘,███,"How does truncation relate to discounting?",
114,HE,⬘⬘⬘,███,"Is truncated flow the same as using a very low discount rate?",
115,GP,⬘⬘⬘,███,"What does ""risk neutral"" mean in this context?",
116,HE,⬘⬘⬘,███,"Why is the base framework risk neutral?",
117,PH,⬘⬘◯,██░,"Shouldn't health policy be risk averse?",
118,MA,⬘⬘⬘,███,"How do you add risk aversion to the framework?",
119,MA,⬘⬘⬘,███,"What is the mean-variance objective and when is it appropriate?",
120,MA,⬘⬘⬘,███,"What is CVaR and why use it instead of variance?",
121,PM,⬘◯◯,█░░,"How do you choose the risk aversion parameter λ or α?",
122,PM,⬘⬘◯,██░,"Is risk neutrality ever the right choice for health policy?",
123,HE,⬘⬘⬘,███,"Why treat irreversibility separately from quality?",
124,HE,⬘⬘⬘,███,"What is ""option value loss"" and why does it matter?",
125,PH,⬘⬘◯,█░░,"Should irreversibility be a penalty or a constraint?",
126,HE,⬘◯◯,█░░,"How do you set the irreversibility penalty κ(x)?",
127,MD,⬘⬘◯,██░,"What if we disagree about which states are irreversible?",
128,PH,⬘◯◯,█░░,"How does irreversibility relate to disability rights arguments?",
129,PH,⬘⬘◯,██░,"Doesn't treating irreversibility as a penalty devalue disabled lives?",
130,GP,⬘⬘⬘,███,"Why does volatility matter if the average is the same?",
131,MD,⬘⬘◯,██░,"What causes cycle-to-cycle volatility in quality?",
132,MD,⬘⬘◯,██░,"Is Assumption 5 (minimum cycle length) realistic?",
133,HE,⬘⬘◯,██░,"How do you estimate variance of q̄^π from data?",
134,PH,⬘◯◯,█░░,"What if people prefer some volatility (e.g., for hope)?",
135,MA,⬘⬘⬘,███,"Does an optimal policy always exist?",
136,MA,⬘⬘⬘,███,"What if there are infinitely many policies?",
137,MA,⬘⬘⬘,███,"Why is the finite-state case easier?",
138,MA,⬘⬘⬘,██░,"What computational methods can find optimal policies?",
139,MA,⬘⬘⬘,███,"How does linear-fractional programming work for this problem?",
140,MA,⬘⬘⬘,███,"What is average-reward dynamic programming?",
141,MA,⬘⬘◯,██░,"Can reinforcement learning methods be applied?",
142,MA,⬘⬘◯,██░,"How does the optimization scale with state space size?",
143,MA,⬘⬘◯,██░,"Are there approximate methods for large state spaces?",
144,PM,⬘⬘⬘,███,"How do you compare two policies when one is better on J and worse on K?",
145,PM,⬘⬘⬘,██░,"What is the willingness-to-pay parameter λ and how is it set?",
146,HE,⬘⬘⬘,██░,"Is W_λ(f) = J(f) - λK(f) the only way to combine quality and cost?",
147,MA,⬘⬘⬘,███,"What if costs are uncertain—does the framework handle stochastic costs?",
148,GP,⬘⬘⬘,███,"What does ""Lipschitz stability"" mean in plain language?",
149,PM,⬘⬘⬘,███,"Why is stability important for policy decisions?",
150,HE,⬘⬘⬘,███,"What could cause instability in the QALY flow metric?",
151,HE,⬘⬘◯,██░,"How do you verify Assumptions 4 and 5 (uniform bounds, Lipschitz) in practice?",
152,MA,⬘⬘⬘,███,"Can you prove Theorem 3 (Lipschitz stability)?",
153,MA,⬘⬘⬘,██░,"What is the Lipschitz constant (L_R + L_τ)/m and is it tight?",
154,MA,⬘⬘⬘,███,"What happens when the lower bound m approaches zero?",
155,HE,⬘⬘◯,██░,"How does this compare to sensitivity analysis in traditional CEA?",
156,HE,⬘⬘◯,██░,"How do you propagate uncertainty through the QALY flow calculation?",
157,HE,⬘⬘⬘,██░,"Should you do probabilistic sensitivity analysis with this framework?",
158,HE,⬘⬘◯,██░,"What parameters are typically most uncertain?",
159,HE,⬘◯◯,█░░,"How do you handle model uncertainty (not just parameter uncertainty)?",
160,HE,⬘⬘◯,██░,"Does the framework support value of information analysis?",
161,HE,⬘⬘⬘,███,"How is the flow ICER different from the standard ICER?",
162,HE,⬘⬘⬘,███,"What are the units of the flow ICER?",
163,HE,⬘⬘⬘,███,"Can flow ICER be negative? What does that mean?",
164,PM,⬘⬘⬘,██░,"How do you interpret a flow ICER of £20,000 per unit J?",
165,PM,⬘◯◯,█░░,"Should regulators set a threshold for flow ICER?",
166,HE,⬘◯◯,█░░,"How would existing NICE thresholds translate to this framework?",
167,HE,⬘⬘◯,██░,"Does the flow ICER avoid problems with extended dominance?",
168,PM,⬘⬘⬘,███,"How do you assess budget impact using cost flow K(π)?",
169,PM,⬘⬘◯,██░,"Can you use this framework for multi-year budget planning?",
170,PM,⬘⬘⬘,███,"How does K(π) relate to annual health expenditure?",
171,HE,⬘⬘◯,██░,"Does the framework account for capital costs vs. operating costs?",
172,PM,⬘⬘◯,██░,"How do you assign equity weights w_i to different groups?",
173,PH,⬘◯◯,█░░,"Should weights be based on health need, income, or something else?",
174,PH,⬘⬘◯,██░,"How does this relate to the ""fair innings"" argument?",
175,PH,⬘⬘◯,██░,"Can the framework handle intersectional inequalities?",
176,HE,⬘⬘⬘,███,"What if groups have different quality functions q_i(x)?",
177,HE,⬘⬘⬘,███,"What is inequality-averse social welfare and why use concave u?",
178,PH,⬘◯◯,█░░,"How do you choose the social welfare function?",
179,PH,⬘⬘⬘,███,"Can you use Rawlsian maximin with this framework?",
180,PM,⬘⬘⬘,██░,"What is the ""minimum acceptable flow"" constraint and who sets it?",
181,LE,⬘◯◯,█░░,"Is there a human right to a certain QALY flow?",
182,PH,⬘⬘⬘,███,"Does the framework treat current and future generations equally?",
183,HE,⬘⬘◯,██░,"How do you handle population growth in the distributional analysis?",
184,PH,⬘⬘◯,██░,"What if future generations will have different quality functions?",
185,PM,⬘◯◯,█░░,"Does this framework conflict with sustainability considerations?",
186,PH,⬘⬘⬘,██░,"Is the framework committed to welfarism?",
187,PH,⬘⬘◯,██░,"Can the framework accommodate objective list theories of well-being?",
188,PH,⬘⬘◯,██░,"What about preference satisfaction views?",
189,PH,⬘⬘◯,██░,"Does the focus on experience ignore the value of achievements?",
190,PH,⬘◯◯,█░░,"How does this relate to Parfit's work on personal identity?",
191,PH,⬘◯◯,█░░,"If someone is uploaded to a digital substrate, does the framework still apply?",
192,PH,⬘⬘◯,██░,"Does the framework assume psychological continuity theory of identity?",
193,PH,⬘⬘◯,█░░,"What if ""I"" in 200 years is not really ""me""?",
194,PH,⬘◯◯,█░░,"Does extreme longevity create problems for personal identity?",
195,PH,⬘⬘◯,██░,"Should QALYs be discounted for psychological distance?",
196,PH,⬘◯◯,█░░,"How does the framework handle amnesia or major personality changes?",
197,PH,⬘⬘⬘,███,"Does the framework assume life is always preferable to death?",
198,PH,⬘⬘◯,██░,"What about cases where someone rationally prefers death?",
199,LE,⬘⬘◯,██░,"Does the framework respect the ""right to die""?",
200,HE,⬘⬘⬘,███,"How does the framework handle states worse than death?",
201,HE,⬘⬘⬘,███,"Can q(x) be negative?",
202,HE,⬘⬘◯,██░,"What is the implicit value of a statistical life in this framework?",
203,PH,⬘⬘◯,██░,"Does the framework have a position on the ""repugnant conclusion""?",
204,PH,⬘⬘◯,██░,"Is adding new lives (via the regeneration assumption) good or neutral?",
205,PH,⬘⬘⬘,███,"How does this relate to total vs. average utilitarianism?",
206,PH,⬘⬘⬘,██░,"Does the framework favor extending existing lives or creating new ones?",
207,PH,⬘◯◯,█░░,"What is the framework's position on the non-identity problem?",
208,HE,⬘⬘⬘,███,"Why not just use standard discounted QALYs with a low discount rate?",
209,MA,⬘⬘⬘,███,"What discount rate would make discounted QALYs equivalent to QALY flow?",
210,HE,⬘⬘⬘,██░,"Does the framework make discounting obsolete?",
211,PH,⬘⬘◯,██░,"What if society genuinely has pure time preference?",
212,HE,⬘⬘◯,██░,"How does hyperbolic discounting fit into this framework?",
213,HE,⬘⬘◯,██░,"Can you combine QALY flow with some discounting?",
214,HE,⬘⬘⬘,███,"How does QALY flow relate to HALE (Health-Adjusted Life Expectancy)?",
215,HE,⬘⬘◯,██░,"Can QALY flow be computed from HALE data?",
216,PM,⬘⬘⬘,███,"What does QALY flow add beyond existing population health measures?",
217,HE,⬘⬘⬘,███,"Could you define a DALY flow analogous to QALY flow?",
218,HE,⬘⬘◯,██░,"How would the axioms change for burden-of-disease measurement?",
219,HE,⬘⬘◯,██░,"Does the Global Burden of Disease study use anything like this?",
220,PH,⬘◯◯,█░░,"How does this compare to the capability approach?",
221,HE,⬘⬘◯,██░,"What about wellbeing-adjusted life years (WELLBYs)?",
222,HE,⬘⬘◯,██░,"How does this relate to the ""health years equivalent"" concept?",
223,HE,⬘⬘◯,██░,"Is this compatible with multi-criteria decision analysis?",
224,HE,⬘⬘◯,██░,"What data would you need to implement this framework?",
225,HE,⬘⬘◯,██░,"Can this be estimated from existing health surveys?",
226,MA,⬘⬘◯,██░,"How do you estimate transition rates for very rare events?",
227,HE,⬘⬘◯,██░,"What longitudinal data sources would be most useful?",
228,MD,⬘⬘◯,██░,"Can electronic health records be used for calibration?",
229,HE,⬘⬘⬘,██░,"How do you calibrate the quality function q(x)?",
230,HE,⬘⬘⬘,██░,"What if different EQ-5D tariffs give different q values?",
231,HE,⬘⬘◯,██░,"How do you handle states not covered by existing instruments?",
232,PH,⬘⬘◯,█░░,"Should q be calibrated to community or patient preferences?",
233,HE,⬘⬘◯,██░,"How do you calibrate costs c(x,a)?",
234,HE,⬘◯◯,█░░,"How would you validate a QALY flow model?",
235,HE,⬘◯◯,█░░,"What would count as evidence that the framework works?",
236,HE,⬘⬘◯,██░,"Can you back-test against historical health data?",
237,MA,⬘⬘◯,██░,"How do you check that the model predicts out-of-sample?",
238,PM,⬘⬘◯,██░,"How would a regulator use this framework in practice?",
239,HE,⬘⬘◯,██░,"What would a QALY flow-based health technology assessment look like?",
240,PM,⬘⬘◯,██░,"How do you communicate QALY flow results to policymakers?",
241,MD,⬘⬘◯,██░,"Should patients understand QALY flow?",
242,PM,⬘⬘◯,██░,"How do you handle disagreement about model parameters?",
243,LE,⬘◯◯,█░░,"Is QALY flow compatible with existing health law?",
244,LE,⬘◯◯,█░░,"Could this framework be challenged on discrimination grounds?",
245,LE,⬘◯◯,█░░,"How does this interact with the right to health?",
246,LE,⬘◯◯,█░░,"What are the implications for insurance regulation?",
247,LE,⬘◯◯,█░░,"Could this affect clinical negligence standards?",
248,LE,⬘◯◯,█░░,"How would FDA/EMA evaluate drugs using this framework?",
249,LE,⬘◯◯,█░░,"Does this framework have implications for informed consent?",
250,LE,⬘◯◯,█░░,"How does it interact with age discrimination law?",
251,MD,⬘⬘◯,██░,"How would you apply this to cancer treatment evaluation?",
252,MD,⬘⬘◯,██░,"What about chronic disease management (diabetes, heart disease)?",
253,MD,⬘⬘◯,██░,"How does this apply to mental health conditions?",
254,MD,⬘⬘◯,██░,"What about rare diseases with uncertain prognosis?",
255,MD,⬘⬘◯,██░,"How would you evaluate aging interventions (senolytics, etc.)?",
256,MD,⬘⬘◯,██░,"What about organ replacement or regeneration?",
257,MD,⬘◯◯,█░░,"How would brain-computer interfaces be evaluated?",
258,HE,⬘⬘⬘,███,"How would you evaluate preventive vs. curative interventions?",
259,PM,⬘⬘⬘,██░,"What about public health interventions (vaccines, sanitation)?",
260,MD,⬘⬘◯,██░,"How would you evaluate lifestyle interventions?",
261,MD,⬘⬘◯,██░,"What about genetic therapies with permanent effects?",
262,MD,⬘⬘⬘,██░,"How would you evaluate palliative care?",
263,PH,⬘⬘⬘,███,"What if a treatment makes you immortal but paralyzed?",
264,HE,⬘⬘⬘,███,"What about treatments that extend lifespan but reduce quality?",
265,HE,⬘⬘⬘,███,"How do you evaluate a treatment that has a small chance of cure and a large chance of death?",
266,HE,⬘⬘⬘,███,"What about treatments that work for some people but not others?",
267,HE,⬘⬘⬘,███,"How do you handle treatments with very long lag times before benefit?",
268,HE,⬘⬘⬘,███,"Isn't this just discounting with r=0?",
269,PH,⬘⬘◯,█░░,"Why should we accept the axioms?",
270,HE,⬘⬘⬘,███,"Doesn't the regeneration assumption make this population-level not individual-level?",
271,MA,⬘⬘⬘,███,"What if the axioms are mutually inconsistent?",
272,MA,⬘⬘◯,██░,"Is there a representation theorem showing these axioms uniquely determine J(π)?",
273,MA,⬘⬘◯,██░,"What alternative objectives could satisfy the same axioms?",
274,PM,⬘⬘◯,██░,"Is this too complicated for real-world use?",
275,HE,⬘⬘◯,██░,"Doesn't this require too much data?",
276,MA,⬘⬘◯,██░,"How can you validate predictions about unbounded lifespans with finite data?",
277,PM,⬘⬘⬘,██░,"Isn't this premature given current life expectancy?",
278,PM,⬘⬘⬘,███,"What if longevity technology never arrives—is this framework still useful?",
279,PH,⬘⬘⬘,███,"Doesn't this devalue the lives of people who die young?",
280,PH,⬘⬘◯,██░,"Is it fair to evaluate policies based on an assumption most people alive today won't benefit from?",
281,PH,⬘⬘◯,██░,"Doesn't the person-time focus ignore individual rights?",
282,PH,⬘◯◯,█░░,"Is this a form of ""welfarist imperialism""?",
283,PH,⬘⬘⬘,███,"What about people who don't want extended lifespans?",
284,PH,⬘⬘◯,██░,"Does this framework respect diversity in conceptions of the good life?",
285,HE,⬘⬘◯,██░,"How would you extend this to multiple populations?",
286,HE,⬘⬘◯,██░,"Can the framework handle correlated individual outcomes (epidemics)?",
287,HE,⬘◯◯,█░░,"How would you model healthcare capacity constraints?",
288,MA,⬘◯◯,█░░,"Can this be extended to game-theoretic settings?",
289,MA,⬘◯◯,█░░,"How would you incorporate learning about treatment effects?",
290,MA,⬘◯◯,█░░,"Can the framework handle ambiguity (Knightian uncertainty)?",
291,HE,⬘⬘⬘,██░,"Should there be a ""second panel"" for unbounded-lifespan methodology?",
292,HE,⬘⬘◯,█░░,"What should guidelines for QALY flow analysis look like?",
293,HE,⬘⬘◯,██░,"How should uncertainty be reported in QALY flow analyses?",
294,HE,⬘◯◯,█░░,"What training would analysts need?",
295,HE,⬘⬘◯,█░░,"What empirical studies would most advance this agenda?",
296,MA,⬘⬘◯,█░░,"What theoretical results are most needed?",
297,HE,⬘◯◯,█░░,"What interdisciplinary work is required?",
298,PM,⬘◯◯,█░░,"How should this research be funded?",
299,GP,⬘⬘⬘,███,"Who is the intended audience for this paper?",
300,PM,⬘⬘◯,█░░,"What would it take to convince skeptics of this approach?",
301,PH,⬘⬘◯,██░,"What are the strongest arguments against this framework?",
302,MA,⬘⬘◯,██░,"What would falsify this framework?",
303,PH,⬘⬘⬘,███,"Is this framework normative or positive?",
304,GP,⬘◯◯,█░░,"What are the authors' own views that are not in the paper?",
305,HE,⬘⬘◯,██░,"What is the intellectual history of this idea?",
306,HE,⬘⬘⬘,███,"How does this relate to the work of Bauer, Lakdawalla, and Reif?",
307,MA,⬘⬘◯,██░,"What role did renewal-reward theory play in other fields before health economics?",
308,HE,⬘⬘◯,██░,"Are there any prior attempts at similar frameworks?",
309,PM,⬘⬘◯,█░░,"If this framework were adopted, how would it change health priorities?",
310,PM,⬘◯◯,█░░,"Would this increase or decrease health spending?",
311,PH,⬘⬘◯,██░,"Would this favor young or old patients?",
312,PM,⬘◯◯,█░░,"How would this affect the politics of health policy?",
313,LE,⬘⬘◯,██░,"Could this be used to justify rationing?",
314,PM,⬘◯◯,█░░,"What are the unintended consequences of adopting this framework?",
315,MD,⬘⬘◯,█░░,"Would this change incentives for medical research?",
316,MA,⬘⬘⬘,██░,"Can you provide an alternative proof of Proposition 1?",
317,MA,⬘⬘⬘,███,"What happens if we allow q(x) > 1 or q(x) < 0?",
318,MA,⬘⬘◯,██░,"Is boundedness preserved under the extensions (risk, irreversibility)?",
319,MA,⬘⬘⬘,███,"What is the proof of the renewal-reward theorem?",
320,MA,⬘⬘◯,██░,"Does the theorem extend to non-i.i.d. cycles?",
321,MA,⬘⬘◯,██░,"What are the weakest conditions under which the theorem holds?",
322,MA,⬘⬘◯,██░,"Is the convergence uniform over policies?",
323,MA,⬘⬘◯,██░,"Can you give a counterexample where the theorem fails?",
324,MA,⬘⬘⬘,███,"Is the proof of Theorem 2 complete as given?",
325,MA,⬘⬘◯,██░,"Can you extend to countable state spaces?",
326,MA,⬘⬘◯,██░,"What if some policies have undefined J(f)?",
327,MA,⬘⬘⬘,███,"Is the optimal policy unique?",
328,MA,⬘⬘◯,██░,"Is the Lipschitz bound tight? Can you achieve equality?",
329,MA,⬘⬘⬘,███,"What happens if Assumption 4 (lower bound m) is violated?",
330,MA,⬘◯◯,█░░,"Can you get Hölder continuity with weaker assumptions?",
331,MA,⬘⬘⬘,███,"How does the proof use the ratio structure of J(π)?",
332,MA,⬘⬘⬘,███,"What is the ""inspection paradox"" mentioned in the proof?",
333,MA,⬘⬘◯,██░,"How does this relate to Palm calculus?",
334,MA,⬘⬘◯,██░,"Can you make the convergence quantitative?",
335,PM,⬘⬘◯,██░,"If a policy gives J = 0.9 but K is very high, should we adopt it?",
336,PH,⬘⬘◯,██░,"Suppose two policies have the same J but different cycle length distributions—should we prefer one?",
337,PH,⬘⬘⬘,███,"What if a policy maximizes J but only for a privileged group?",
338,PH,⬘⬘◯,█░░,"Imagine a treatment that grants immortality but at quality 0.3—is it worth pursuing?",
339,PH,⬘⬘◯,█░░,"What if we could guarantee J = 1 for everyone at infinite cost—what's the right policy?",
340,MA,⬘⬘⬘,███,"Suppose cycle lengths become so long that no one ever completes a cycle—does the framework break?",
341,MA,⬘⬘⬘,███,"What if a treatment eliminates catastrophic failure entirely—what happens to the regeneration assumption?",
342,PH,⬘⬘◯,██░,"Imagine two societies with identical J but different distributions of cycle outcomes—which is better?",
343,PH,⬘⬘◯,█░░,"What if people could choose their own q function—should we let them?",
344,PH,⬘◯◯,█░░,"Suppose an alien civilization offers immortality but you must leave Earth—how do we evaluate?",
345,PH,⬘◯◯,█░░,"What if memory could be erased after each ""cycle""—does personal identity matter?",
346,PH,⬘⬘◯,██░,"Imagine a treatment that cures all disease but causes sterility—how do we evaluate with this framework?",
347,PH,⬘◯◯,█░░,"What if AI systems could experience quality-of-life—should they be in the framework?",
348,PM,⬘⬘◯,██░,"Suppose some people value extreme longevity and others don't—can one framework serve both?",
349,PH,⬘⬘◯,██░,"What if the quality function changes over time as society evolves—is J(π) still meaningful?",
350,PH,⬘⬘◯,█░░,"Imagine we discover death has positive externalities (new ideas from new people)—does this change anything?",
351,GP,⬘⬘⬘,██░,"What is the single most important takeaway from this paper?",
352,GP,⬘⬘◯,█░░,"What would the authors want readers to do after reading this?",
353,GP,⬘◯◯,█░░,"If you could ask the authors one question, what would it be?",
354,HE,⬘⬘◯,█░░,"What's missing from this paper that should be there?",
355,HE,⬘⬘◯,█░░,"What's the next paper that should be written following this one?",
356,GP,⬘◯◯,█░░,"In 50 years, will this paper be remembered? Why or why not?",
357,PM,⬘⬘◯,█░░,"What would change if this framework were universally adopted?",
358,PM,⬘⬘◯,██░,"What's the biggest obstacle to adoption?",
359,MA,⬘⬘◯,██░,"What would make this paper wrong?",
360,PM,⬘⬘◯,██░,"What would make this paper unnecessary?"
